Mutations found in cell‐free DNAs of patients with malignant lymphoma at remission can derive from clonal hematopoiesis by 坂田（柳元） 麻実子 et al.
Mutations found in cell‐free DNAs of patients
with malignant lymphoma at remission can
derive from clonal hematopoiesis
著者（英） Yasuhito Suehara, Mamiko SAKATA-YANAGIMOTO,
Keiichiro Hattori, Manabu Kusakabe, Toru
Nanmoku, Taiki Sato, Masayuki NOGUCHI, Shigeru
CHIBA
journal or
publication title
Cancer Science
volume 110
number 10
page range 3375-3381
year 2019-10
権利 (C) 2019 The Authors. Cancer Science published
by John Wiley & Sons Australia, Ltd on behalf
of Japanese Cancer Association.
This is an open access article under the terms
of the Creative Commons Attribution‐
NonCommercial‐NoDerivs License, which permits
use and distribution in any medium, provided
the original work is properly cited, the use
is non‐commercial and no modifications or
adaptations are made.
URL http://hdl.handle.net/2241/00159546
doi: 10.1111/cas.14176
Creative Commons : 表示 - 非営利 - 改変禁止
http://creativecommons.org/licenses/by-nc-nd/3.0/deed.ja
Cancer Science. 2019;110:3375–3381.	 	 	 | 	3375wileyonlinelibrary.com/journal/cas
 
Received:	29	January	2019  |  Revised:	2	July	2019  |  Accepted:	14	August	2019
DOI:	10.1111/cas.14176		
O R I G I N A L  A R T I C L E
Mutations found in cell‐free DNAs of patients with malignant 
lymphoma at remission can derive from clonal hematopoiesis
Yasuhito Suehara1,2  |   Mamiko Sakata‐Yanagimoto2,3 |   Keiichiro Hattori2  |   
Manabu Kusakabe2,3  |   Toru Nanmoku4 |   Taiki Sato5 |   Masayuki Noguchi5 |   
Shigeru Chiba2,3,6
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution‐NonCommercial‐NoDerivs	License,	which	permits	use	and	distribution	in	
any	medium,	provided	the	original	work	is	properly	cited,	the	use	is	non‐commercial	and	no	modifications	or	adaptations	are	made.
©	2019	The	Authors.	Cancer Science	published	by	John	Wiley	&	Sons	Australia,	Ltd	on	behalf	of	Japanese	Cancer	Association.
1Department	of	Hematology,	Graduate	
School	of	Comprehensive	Human	
Sciences,	University	of	Tsukuba,	Tsukuba,	
Japan
2Department	of	Hematology,	University	of	
Tsukuba	Hospital,	Tsukuba,	Japan
3Department	of	Hematology,	Faculty	of	
Medicine,	University	of	Tsukuba,	Tsukuba,	
Japan
4Department	of	Clinical	
Laboratory,	University	of	Tsukuba	Hospital,	
Tsukuba,	Japan
5Department	of	Pathology,	Faculty	of	
Medicine,	University	of	Tsukuba,	Tsukuba,	
Japan
6Life	Science	Center	for	Survival	
Dynamics,	Tsukuba	Advanced	Research	
Alliance,	University	of	Tsukuba,	Tsukuba,	
Japan
Correspondence
Shigeru	Chiba,	Department	of	Hematology,	
Faculty	of	Medicine,	University	of	Tsukuba,	
Tsukuba,	Ibaraki,	Japan.
Email:	schiba‐tky@umin.net
Funding information
Japan	Agency	for	Medical	Research	and	
Development;	The	Ministry	of	Education,	
Culture,	Sports,	Science	and	Technology	
of	Japan,	Grant/Award	Number:	16H2660,	
18H02834	and	18K19464;	Japanese	Society	
of	Hematology
Abstract
Cell‐free	DNA	(cfDNA)	analysis	to	detect	circulating	tumor	DNA	has	been	focused	
on	monitoring	malignant	 lymphomas.	However,	clonal	hematopoiesis	of	 indetermi‐
nate	potential	(CHIP)‐associated	mutations	can	also	be	detected	by	cfDNA	analysis.	
Our	aim	 is	 to	 investigate	 the	origin	of	mutations	detected	 in	cfDNA	among	B‐cell	
lymphoma	patients.	MYD88/CD79B, DNMT3A,	 and	TP53	were	 chosen	 as	 genes	of	
interest,	 representing	 each	 of	 the	 following	 categories:	 lymphoma	 driver	 genes,	
CHIP‐related	genes,	and	genes	shared	between	 lymphoma	and	CHIP.	Seventy‐five	
B‐cell	lymphoma	patients	were	included	in	this	retrospective	study.	Serum	cfDNAs	
at	time	of	complete	metabolic	response	(CMR)	were	sequenced	for	TP53	(N	=	75)	and	
DNMT3A	(N	=	49).	MYD88	p.L265P	and	CD79B	p.Y196C/H	mutations	were	analyzed	
in	diffuse	large	B‐cell	lymphoma	(DLBCL)	patients	whose	tumor	samples	were	avail‐
able	 (N	=	29).	Two	and	seven	mutations	 in	TP53 and DNMT3A,	 respectively,	were	
detected	in	cfDNA	at	CMR.	These	mutations	were	detected	in	either	bone	marrow	
mononuclear	cells	(BMMC)	or	PBMC.	Although	four	DNMT3A	mutations	were	also	
detected	in	tumors,	median	variant	allele	frequencies	in	the	tumors	(<1.0%)	were	sig‐
nificantly	lower	than	those	in	both	BMMC	(6.1%)	and	serum	(5.2%)	obtained	before	
the	therapy.	Conversely,	five	MYD88	and	three	CD79B	mutations	detected	in	tumors	
were	confirmed	in	cfDNA	before	therapy,	but	not	in	BMMC	nor	in	cfDNA	at	CMR.	
Thus,	all	TP53 and DNMT3A	mutations	detected	 in	cfDNA	at	remission	seemed	to	
originate	from	CHIP	rather	than	from	residual	disease.	Results	of	liquid	biopsy	should	
be	carefully	interpreted,	especially	in	genes	shared	between	lymphomas	and	CHIP.
K E Y W O R D S
B‐cell	lymphoma,	cell‐free	DNA,	circulating	tumor	DNA,	clonal	hematopoiesis	of	
indeterminate	potential,	TP53
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1  | INTRODUC TION
Cell‐free	DNA	(cfDNA)	analysis	to	detect	circulating	tumor‐derived	
DNA	 (ctDNA)	 has	 recently	 been	 used	 to	 focus	 on	 disease	moni‐
toring	 of	 malignancies,	 including	 malignant	 lymphomas	 (ML).1	 It	
enables	us	to	track	minimal	residual	disease	(MRD)	and	clonal	evo‐
lution,	with	minimal	invasiveness.	TP53,	a	tumor	suppressor	gene,	
is	 occasionally	 mutated	 in	 ML	 as	 well	 as	 in	 other	 hematological	
malignancies,	albeit	less	frequently	than	in	many	solid	tumors;	for	
example,	17%,	5%‐12%,	and	9%	 in	newly	diagnosed	diffuse	 large	
B‐cell	lymphoma	(DLBCL),2	follicular	lymphoma	(FL),3	and	Hodgkin	
lymphoma	(HL),4	respectively.	TP53	mutations	have	been	reported	
as	a	poor	prognostic	indicator	of	DLBCL	in	the	R‐CHOP	(rituximab,	
cyclophosphamide,	doxorubicin,	vincristine,	and	prednisone)	ther‐
apy	 era,5	 and	 are	 more	 prevalent	 in	 refractory/relapsed	 DLBCL	
than	in	newly	diagnosed	DLBCL.6,7	Similarly,	 it	has	been	reported	
that	 TP53	 mutations	 are	 more	 prevalent	 in	 transformed	 follicu‐
lar	 lymphoma	 than	 in	 untransformed	 FL.8	 Accordingly,	 detecting	
TP53	mutations	 by	 cfDNA	analysis	 in	 a	 longitudinal	method	may	
be	informative.
Recent	studies	have	shown	that	one	or	more	somatic	mutations	
could	be	detected	in	the	peripheral	blood	cells	of	elderly	individuals	
without	any	history	of	hematological	malignancies.9,10	This	condition	
has	 been	 termed	 clonal	 hematopoiesis	 of	 indeterminate	 potential	
(CHIP).9,10	It	has	been	reported	that	relative	risk	of	developing	hema‐
tological	malignancies	is	greater	in	individuals	with	detectable	CHIP	
than	 in	 those	 without.9,10	 Mutations	 in	 CHIP	 are	 most	 frequently	
found	in	DNMT3A	(50%‐60%),9,10	followed	by	some	cancer‐associated	
genes	including	TP53.	Retrospective	studies	have	shown	a	higher	risk	
of	developing	therapy‐related	myeloid	neoplasms	(t‐MN)	in	cancer	pa‐
tients	with	TP53	CHIP	mutations	at	initial	cancer	diagnosis.11‐13
Tumor	cells	and	blood	cells	are	thought	to	be	major	sources	of	
cfDNAs.14,15	Hence,	mutations	detected	in	cfDNAs	of	patients	with	
malignancies	can	derive	 from	either	or	both	 tumor	cells	and	CHIP	
cells.	Our	aim	is	to	investigate	the	origin	of	CHIP‐related	gene	muta‐
tions	detected	in	serum	cfDNAs	from	patients	with	B‐cell	lymphoma	
(including	HL).	For	this	purpose,	TP53,	which	is	found	in	both	B‐cell	
lymphomas	and	CHIP,	DNMT3A,	which	 is	 the	most	 frequent	CHIP	
gene	and	is	rare	in	B‐cell	lymphomas,	and	CD79B/MYD88,	which	are	
recurrently	mutated	in	14%	and	18%,	respectively,	of	non‐selective	
DLBCL16	and	are	 rarely	present	 in	CHIP,	were	chosen	as	genes	of	
interest.
2  | MATERIAL S AND METHODS
Seventy‐five	 patients	with	 a	 diagnosis	 of	 B‐cell	 lymphoma	whose	
archived	 serum	 samples	 at	 the	 time	 of	 complete	 metabolic	 re‐
sponse	 (CMR)	 were	 available	 were	 included	 in	 this	 retrospective	
study.	Serum	cfDNAs	obtained	at	the	time	of	CMR	from	all	patients	
were	 sequenced	 for	TP53	 (N	 =	 75)	 and	DNMT3A	 (N	 =	 49)	 (Figure	
S1).	Among	the	patients	who	showed	mutations	in	serum	cfDNAs	at	
the	time	of	CMR,	the	following	samples	were	sequenced	by	targeted	
amplicon‐based	 deep	 sequencing:	 (i)	 bone	 marrow	 mononuclear	
cells	 (BMMC),	 serum,	 and	 tumors,	 all	 of	which	had	been	obtained	
before	 therapy;	 and	 (ii)	 BMMC	 or	 PBMC	 obtained	 at	 the	 time	 of	
CMR	 (Figure	 S1).	Only	BMMC	and	PBMC	with	 undetectable	 lym‐
phoma	cells	were	analyzed.	For	patients	with	DLBCL	whose	tumor	
samples	were	available	(N	=	29),	L265P	MYD88	and	Y196C/H	CD79B 
mutations	were	analyzed	using	droplet	digital	PCR	(ddPCR)	(Figure	
S2).	Among	the	patients	who	showed	mutations	in	the	tumors,	the	
following	samples	were	also	analyzed:	(i)	BMMC	and	serum	obtained	
before	therapy;	and	(ii)	serum	obtained	at	the	time	of	CMR.	Variant	
allele	 frequencies	 (VAF)	were	 assessed	 to	 compare	mutations	 be‐
tween	mononuclear	cells,	serum	and	tumors.	Haploid	genome	equiv‐
alents	per	milliliter	(hGE/mL),	which	is	determined	as	the	product	of	
VAF	and	total	cell‐free	DNA	concentration,	was	assessed	to	quan‐
titate	 levels	 of	mutations	 in	 cfDNA	before	 and	 after	 therapy.	 The	
study	was	approved	by	the	review	board	of	University	of	Tsukuba	
Hospital,	and	was	conducted	in	accordance	with	the	Declaration	of	
Helsinki.
2.1 | DNA extraction
The	cfDNAs	were	extracted	from	1	mL	serum	using	a	QIAamp	circu‐
lating	nucleic	acid	kit	(Qiagen).	Serum	was	separated	within	6	hours,	
respectively,	 after	 blood	 collection.	Blood	 samples	were	 collected	
into	tubes	with	serum	separator	or	 tubes	with	heparin	and	centri‐
fuged	at	1750	×g	 for	15	minutes	at	room	temperature.	Serum	was	
transferred	into	cryogenic	vials	(Corning)	and	stored	at	−80°C	until	
DNA	extraction.	Tumor	DNAs	were	extracted	from	archived	forma‐
lin‐fixed	 paraffin‐embedded	 (FFPE)	 specimens	 using	 a	 GeneRead	
FFPE	kit	 (Qiagen).	Tumor	purity	of	the	specimen	was	evaluated	by	
a	pathologist.	DNA	was	extracted	from	cryopreserved	BMMC	and	
PBMC	samples	using	a	DNA	mini	kit	(Qiagen).	Extracted	DNAs	were	
stored	at	−20°C	until	analysis.
2.2 | Primer designs, constructing libraries, and 
variant calling pipelines in sequencing
Sequencing	 for	 TP53 and DNMT3A	 was	 carried	 out	 using	 Ion	
Torrent	Personal	Genome	Machine	(Thermo	Fisher	Scientific).	Ion	
Ampliseq	 Custom	 Panels	 for	 DNMT3A and TP53	 were	 designed	
using	online	Ion	Ampliseq	Designer	(Thermo	Fisher	Scientific).	The	
gene	panel	 for	DNMT3A	was	composed	of	75	amplicons,	 sizes	of	
which	were	125	to	140	base	pairs	(bp),	totaling	6.09	kilobases.	That	
for	TP53	was	composed	of	38	amplicons,	sizes	of	which	were	125	
to	140	bp,	 totaling	2.97	 kilobases.	 Libraries	were	prepared	using	
an	Ion	Ampliseq	Library	Kit	2.0	(Thermo	Fisher	Scientific).	For	tar‐
geted	amplicon‐based	deep	sequencing,	each	primer	was	designed	
individually	 using	Primer	3	 and	Primer‐BLAST	 (Table	 S1).	 Torrent	
Suite	version	5.8	software	(Thermo	Fisher	Scientific)	was	used	to	
carry	out	signal	processing,	base	calling,	and	sequence	alignment	
to	 the	 reference	 genome	 (hg19).	 Variant	 caller	 plugin	 was	 used	
with	the	following	settings:	(i)	minimum	allele	frequency	=	0.02	for	
screening,	0.01	for	targeted	amplicon‐based	deep	sequencing;	 (ii)	
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minimum	Phred	 quality	 score	 =	 6;	 (iii)	minimum	 coverage	 =	 100;	
(iv)	minimum	 coverage	 on	 either	 strand	 =	 4;	 (v)	maximum	 strand	
bias	=	0.95;	(vi)	maximum	common	signal	shift	=	0.12.	Synonymous	
variants,	intronic	and	UTR	variants,	variants	curated	in	dbSNP,	and	
variants	 whose	 allele	 frequency	 was	 40.0‐60.0	 or	 80.0‐100.0%	
were	 filtered	 out.	Variants	 detected	 in	 cfDNAs	but	 not	 in	 tumor	
DNAs	nor	 in	BMMC/PBMC‐derived	DNAs	were	also	filtered	out.	
All	variants	were	 inspected	manually	using	an	 integrated	genome	
viewer.
2.3 | Droplet digital PCR
MYD88	 p.L265P,	CD79B	 p.Y196C,	 and	CD79B	 p.Y196H	were	 ana‐
lyzed	 using	 ddPCR.	 Predesigned	 primers	 and	 FAM‐	 and	 HEX‐la‐
beled	TaqMan	probes	were	used	for	the	detection	of	the	following	
variants:	 c.794T>C	 (L265P)	 MYD88	 mutation	 (Bio‐Rad,	 Assay	 ID:	
dHsaMDS2516944);	 c.587A>G	 (Y196C)	CD79B	mutation	 (Bio‐Rad,	
Assay	ID:	dHsaMDS717317229);	and	c.586T>C	(Y196H)	CD79B mu‐
tation	(Bio‐Rad,	Assay	ID:	dHsaMDS540972798).
Distilled	water	 controls,	 negative	 and	 positive	 controls	were	 in‐
cluded	in	each	run.	The	assay	was	carried	out	using	the	QX200	ddPCR	
system	(Bio‐Rad).	PCR	amplification	was	carried	out	as	follows:	initial	
enzyme	activation	at	95°C	for	10	minutes,	40	cycles	of	denaturation	
and	 annealing/extension	 at	 94°C	 for	 30	 seconds,	 hold	 at	 56°C	 for	
1	minute,	and	then	enzyme	deactivation	at	98°C	for	10	minutes.	The	
ramp	rate	was	at	2°C/second	throughout	the	entire	amplification	pro‐
cess.	Results	were	analyzed	using	QuantaSoft	version	1.7.4.	(Bio‐Rad).	
Lower	limit	of	detection	(LOD)	for	L265P	MYD88	was	fractional	abun‐
dance	of	0.1%	as	previously	described.17	LOD	for	Y196H	and	Y196C	
CD79B	 were	 determined	 as	 0.12%	 and	 0.037%	 each	 by	 a	 dilution	
study	(Figure	S3).
2.4 | Statistical analysis
Statistical	 analysis	 was	 carried	 out	 using	 R	 version	 3.5.2.	
Categorical	 and	 continuous	 data	 were	 analyzed	 using	 Fisher's	
exact	 test	 and	Wilcoxon	 rank	 sum	 test.	 Kruskal‐Wallis	 one‐way	
analysis	 of	 variance	 (Kruskal‐Wallis	 ANOVA)	 and	 post‐hoc	 test	
with	Bonferroni	correction	were	used	to	compare	VAF	of	cfDNA,	
tumor,	PBMC/BMMC.
3  | RESULTS
3.1 | Patient characteristics
Details	of	patient	characteristics	are	provided	in	Table	1.	Median	
age	 was	 65	 (range:	 25‐89).	 Forty‐five	 (60.0%),	 20	 (26.7%),	 six	
(8.0%),	 and	 four	 (5.3%)	 patients	 were	 diagnosed	 with	 DLBCL,	
FL,	 B‐cell	 lymphomas	 other	 than	DLBCL	 or	 FL,	 and	HL,	 respec‐
tively.	All	patients	except	 for	one	 (1.3%)	who	 received	 radiation	
therapy	 alone	 received	 chemotherapy;	 43	 (57.3%),	 14	 (18.7%),	
four	(5.3%),	two	(2.7%)	and	11	(14.7%)	patients	received	R‐CHOP,	
R‐bendamustine,	ABVD	(doxorubicin,	bleomycin,	vinblastine,	and	
dacarbazine),	 other	 regimens,	 and	more	 than	 two	 regimens, re‐
spectively.	 Eleven	 patients	 received	 chemoradiotherapy.	 During	
the	median	follow	up	of	30.9	months	(range,	6.3‐82.6),	one	patient	
developed	a	 secondary	malignancy	 (aggressive	natural	 killer	 cell	
leukemia,	ANKL).
3.2 | Sequencing depth
Average	 sequencing	 depths	 were	 8009	 and	 3783	 for	 TP53 and 
DNMT3A,	respectively,	in	multiplex	PCR‐based	sequencing.	That	of	
targeted	amplicon‐based	sequencing,	which	was	designed	for	each	
specific	 variant	 detected	 through	 TP53 and DNMT3A	 sequencing,	
was	58	073.	Median	target	base	coverages	with	at	least	500	reads	
were	 100.0%,	 94.1%,	 and	 100.0%	 for	 target	 regions	 of	DNMT3A,	
TP53,	and	each	amplicon.
TA B L E  1  Characteristics	of	patients	in	the	present	study
 
Liquid biopsy at complete 
metabolic response
P 
valueNegative Positive
No.	of	patients 66 9  
Median	age,	y	(range) 63.5	(25‐89) 73	(65‐78) 0.03
Male,	n	(%) 36	(54.5) 7	(77.8) 0.29
Histological	diagnosis,	n	(%)
DLBCL 37	(56.1) 8	(88.9) 0.45
Follicular	lymphoma 19	(28.8) 1	(11.1)
Other	B‐cell	lymphomas 6	(9.1) 0	(0.0)
Hodgkin	lymphoma 4	(6.1) 0	(0.0)
Advanced	clinical	stage,	
n	(%)
38	(57.6) 5	(55.6) 1.00
Bone	marrow	invasion,	
n	(%)
11	(16.7) 0	(0.0) 0.34
LDH	>	upper	normal	limit,	
n	(%)
39	(59.1) 6	(66.7) 0.35
Chemotherapy,	n	(%)
R‐CHOP 36	(54.5) 7	(77.8) 0.72
R‐Bendamustine 12	(18.2) 2	(22.2)
ABVD 4	(6.1) 0	(0.0)
Other 2	(3.0) 0	(0.0)
More	than	2	regimens 11	(16.7) 0	(0.0)
Never	(radiation	alone) 1	(1.5) 0	(0.0)
Radiation	therapy,	n	(%) 9	(13.6) 2	(22.2) 0.61
Median	follow	up,	months	
(range)
31.3 
(6.3‐82.6)
25.6	
(14.1‐48.2)
0.65
Secondary	malignancies,	n	(%)
Aggressive	NK	cell	
leukemia
0	(0.0) 1	(11.1) 0.12
Signficant	P	values	are	shown	in	bold	text.	Abbreviations:	ABVD,	doxo‐
rubicin,	bleomycin,	vinblastine,	dacarbazine;	CHOP,	cyclophosphamide,	
doxorubicin,	vincristine,	and	prednisolone;	DLBCL,	diffuse	large	B‐cell	
lymphoma;	LDH,	lactate	dehydrogenase;	NK,	natural	killer;	R,	rituximab.
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3.3 | Mutations and variant allele frequencies 
before therapy and at the time of complete 
metabolic response
Two	 mutations	 in	 TP53	 (two	 missense	 mutations:	 p.A119D	 and	
p.C275Y)	 and	 seven	 in	 DNMT3A	 (four	 missense	 mutations,	 two	
nonsense	mutations,	one	frameshift	deletion;	p.W860R	in	two	pa‐
tients,	 and	p.V563M,	p.R882H,	p.E392*,	p.W601*,	 and	p.E565	 fs	
in	one	each)	were	detected	in	serum	obtained	at	the	time	of	CMR	
(Table	 S2).	 All	 these	 mutations	 were	 detected	 in	 either	 BMMC	
before	 therapy	or	 in	PBMC/BMMC	at	 the	 time	of	CMR.	For	 the	
seven	 patients	 whose	 tumor	 samples	 before	 the	 therapy	 were	
available,	four	of	five	DNMT3A,	but	none	of	two	TP53	mutations,	
were	also	detected	in	paired	tumors	obtained	before	the	therapy	
(Table	S2).	However,	VAF	 in	 the	 tumors	were	 significantly	 lower	
than	 those	 in	 both	 serum	 and	BMMC	obtained	 before	 the	 ther‐
apy.	Median	 (range)	VAF	of	mutations	were	6.1%	 (<1.0%‐13.8%),	
5.2%	 (<1.0%‐11.4%),	 and	 <1.0%	 (<1.0%‐1.6%)	 in	 BMMC,	 serum,	
and	tumor,	respectively	(Kruskal‐Wallis	ANOVA,	P	=	.01:	Wilcoxon	
rank‐sum	 test	 with	 Bonferroni	 correction,	 BMMC	 vs	 serum,	
P	 =	 1.00;	 BMMC	 vs	 tumor,	 P	 =	 .02;	 serum	 vs	 tumor,	 P	 =	 .03;	
Figure	 1A,	 Table	 S2).	 This	 finding	 suggested	 that	 the	mutations	
detected	in	cfDNAs	may	have	derived	from	CHIP	rather	than	from	
the	tumors.	Moreover,	this	notion	was	strengthened	in	all	of	the	
nine	patients	by	the	following	observations:	 (i)	patients’	age	was	
significantly	higher	in	those	with	TP53 or DNMT3A	mutation	than	
in	those	without	(median,	73.0	vs	63.5	years,	P	=	.03,	Table	1).	This	
was	compatible	with	the	fact	that	CHIP	was	more	prevalent	with	
older	age;9,10	(ii)	median	(range)	VAF	of	PBMC/BMMC	and	serum	
were	4.6%	 (1.3%‐15.3%)	and	6.0%	 (3.2%‐23.8%),	 respectively,	 at	
CMR,	where	residual	tumor	burden	was	extremely	low	(Figure	1B,	
Table	S2).
Furthermore,	we	surveyed	MYD88	p.L265P	(L265P	MYD88)	and	
CD79B	p.Y196C	and	CD79B	p.Y196H	 (Y196C/H	CD79B)	mutations,	
which	were	prevalent	in	DLBCL	as	driver	mutations	and	rare	in	CHIP,	
to	 examine	whether	MRD‐derived	mutation	 could	 be	 detected	 at	
CMR.	Five	L265P	MYD88,	one	Y196C	CD79B,	and	two	Y196H	CD79B 
mutations	were	confirmed	in	six	of	29	DLBCL	tumor	samples.	These	
mutations	were	also	detected	in	serum	cfDNA	before	therapy,	but	
not	in	BMMC	nor	serum	cfDNA	at	CMR.	Median	(range)	fractional	
abundance	of	mutations	were	<0.1	 (<0.1‐<0.12)%,	 7.4	 (0.7‐20.6)%,	
and	 41.1	 (20.5‐82)%	 in	 BMMC,	 serum,	 and	 tumor,	 respectively	
(Kruskal‐Wallis	 ANOVA,	 P	 =	 .0004:	Wilcoxon	 rank	 sum	 test	 with	
Bonferroni	correction,	BMMC	vs	serum,	P	=	.012;	BMMC	vs	tumor,	
P	=	.0048;	serum	vs	tumor,	P	=	.0093;	Figure	2,	Table	S3).	This	re‐
sult	decreased	the	possibility	that	MRD‐derived	mutations	could	be	
detected	 at	 CMR	with	 the	 thresholds	 of	 ddPCR,	which	was	more	
sensitive	 than	 that	 of	 targeted	 sequencing.	 Quantitative	 levels	 of	
TP53 and DNMT3A	mutations	in	serum	were	within	1.15	log‐fold,	ex‐
cept	for	W860R	DNMT3A	mutation	which	was	undetectable	before	
therapy	(Figure	3A).	In	contrast,	quantitative	levels	of	L265P	MYD88 
and	Y196C/H	CD79B	mutations	decreased	more	than	3	log‐fold	and	
were	below	the	threshold	of	detection	(Figure	3B).
3.4 | Longitudinal analysis of a patient with DLBCL 
who developed aggressive NK cell leukemia
One	DLBCL	patient	with	the	TP53	p.A119D	mutation	in	cfDNAs	(on	
day	253)	showed	relapse	on	day	962	and	later	developed	ANKL	on	
day	1296.	VAF	of	the	TP53	p.A119D	were	23.8%	and	15.3%	in	lym‐
phoma‐free	BMMC	and	PBMC,	 respectively	 (Table	2).	 They	were,	
however,	as	low	as	1.8%	in	the	DLBCL	tumor	sample	at	relapse,	and	
undetectable	 in	 the	DLBCL	 tumor	 sample	 at	 diagnosis	 and	 in	 the	
leukemic	 cells	 of	ANKL	with	 a	 threshold	of	1%	 (611	altered	 reads	
per	total	66	086	reads)	(Table	2).	This	implied	that	both	DLBCL	and	
ANKL	 did	 not	 derive	 from	 a	 TP53	 p.A119D‐CHIP‐carrying	 clone.	
Concentrations	of	TP53	p.A119D	in	serum	ranged	within	1.3‐log	fold	
change	throughout	the	entire	course.
4  | DISCUSSION
Liquid	biopsy	sometimes	enables	us	to	detect	relapse	of	tumors	and	
development	of	drug‐resistant	clones	by	longitudinal	sampling	dur‐
ing	the	clinical	course.	However,	our	data	suggested	that	TP53 and 
DNMT3A	mutations	detected	 in	cfDNAs	at	the	time	of	CMR	origi‐
nated	 from	CHIP	 rather	 than	 from	 tumors,	 judging	 from	 the	pres‐
ence	of	mutations	in	mononuclear	cells	and	the	absence	or	minimal	
presence	of	mutations	in	tumors	(Figure	1	and	Table	S2).	Very	low	
variant	 load	 found	 in	 tumors	may	 represent	 intervening	CHIP‐de‐
rived	non‐tumor	cells.	This	phenomenon	has	also	been	reported	in	
next‐generation	sequencing	without	matched	controls.18,19	Similarly,	
TP53	 mutations	 detected	 by	 liquid	 biopsy	 were	 also	 recently	 re‐
ported	to	be	attributed	to	CHIP	in	15%	(5/33)	of	non‐small	cell	lung	
carcinoma	patients.20 DNMT3A and TP53	mutations,	probably	con‐
sidered	as	CHIP,	were	observed	 in	seven	(14.3%)	of	49	and	 in	two	
F I G U R E  1  Comparison	of	variant	
allele	frequencies	(VAF)	among	TP53 and 
DNMT3A	mutations	detected	in	each	
sample	before	and	after	therapy.	BMMC,	
bone	marrow	mononuclear	cells;	CMR,	
complete	metabolic	response;	ND,	not	
detectable;	NS,	not	significant.	*P	<	.05
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(2.7%)	of	75	patients,	respectively.	Prevalence	of	CHIP	in	the	current	
study	was	compatible	with	that	of	the	previous	literature,	in	which	
the	cohort	was	patients	with	lymphoma	and	the	detection	threshold	
of	VAF	was	2%.21
There	 are	 several	 arguments	 against	 the	 interpretation	 that	
mutations	detected	in	cfDNA	originated	only	from	CHIP.	As	a	first	
argument,	 TP53	 mutations	 originated	 from	 the	 B‐cell	 lymphomas.	
Because	regional	heterogeneity	is	not	uncommon,	biopsy	from	dif‐
ferent	 sites	might	 cause	 false‐negativity	 of	TP53	mutations	 in	 the	
tumor‐derived	DNA.	Nevertheless,	≥3‐log	decrease	of	 the	MYD88 
or CD79B	 mutational	 burden	 was	 seen	 in	 cfDNA	 of	 six	 patients,	
whereas TP53	mutational	 burdens	were	 stably	 high	 in	 two	out	 of	
F I G U R E  2  Comparison	of	fractional	
abundance	of	MYD88 and CD79B 
mutations	detected	in	each	sample	before	
and	after	therapy.	BMMC,	bone	marrow	
mononuclear	cells;	CMR,	complete	
metabolic	response;	ND,	not	detectable.	
*P	<	.05;	**P	<	.01;	***P	<	.005	
F I G U R E  3  Longitudinal	assessment	
of	concentrations	in	cell‐free	DNA.	CMR,	
complete	metabolic	response;	hGE/mL,	
haploid	genome	equivalents	per	milliliter;	
ND,	not	detectable
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two.	 Therefore,	 the	 possibility	 that	 the	 TP53	 mutations	 are	 from	
non‐fluorodeoxyglucose	 (FDG)‐avid	 MRD	 lesions	 at	 the	 time	 of	
CMR	should	be	negligible.	As	a	second	argument,	non‐FDG‐avid	oc‐
cult	cancers	other	than	B‐cell	lymphomas	could	be	a	source	of	TP53 
mutations	in	cfDNA.	Even	if	there	was	imaging‐study‐occult	stage	1	
cancer,	in	a	previous	report,	mean	VAF	of	ctDNA	detected	in	stage	
1	cancers	was	0.05%.22	Therefore,	 given	 that	 the	 lower	detection	
limit	of	VAF	in	the	current	study	was	1%,	variants	were	reasonably	
under	this	level.
We	 expected	 that	 DNMT3A	 mutations	 could	 be	 evidence	 for	
CHIP‐associated	mutations	in	B‐cell	lymphomas	because	of	their	rar‐
ity	 in	 this	 category	of	 tumor	at	 study	commencement.	However,	 it	
was	 recently	 reported	 that	DNMT3A and TET2	mutations	were	 re‐
currently	mutated	in	patients	with	Epstein‐Barr	virus	(EBV)‐positive	
DLBCL.23	EBV‐positive	DLBCL	is	an	EBV‐positive	clonal	large	B‐cell	
proliferation,	 with	 the	 exclusion	 of	 several	 specific	 types	 of	 EBV‐
positive	lymphomas,	such	as	plasmablastic	lymphoma.24	It	is	unclear	
whether	DNMT3A and TET2	mutations	detected	in	lymphomas	were	
derived	from	CHIP,	likewise	in	the	pathogenesis	of	angioimmunoblas‐
tic	T‐cell	lymphoma,25	as	targeted	sequencing	analysis	of	lymphoma	
specimens	in	the	study	was	carried	out	in	a	non‐paired	method.23	We	
must	pay	attention	to	DNMT3A	mutations	detected	in	cfDNA	of	pa‐
tients	with	EBV‐positive	DLBCL	unlike	other	subtypes	of	DLBCL	be‐
cause	their	origin	can	be	either	or	possibly	both	CHIP	and	lymphoma.
Kurtz	et	al26	reported	a	2.5‐log	decrease	of	ctDNA	after	two	cy‐
cles	of	R‐CHOP	therapy	in	patients	with	DLBCL	who	were	stratified	
responders	compared	with	non‐responders.	More	than	a	3‐log	de‐
crease	of	all	MYD88 and CD79B	mutations	in	cfDNA	was	compatible	
with	this	previous	literature	because	all	patients	with	DLBCL	in	this	
cohort	had	achieved	CMR.	On	 the	 contrary,	 changes	of	TP53 and 
DNMT3A	mutations	detected	in	cfDNA	were	within	1.3‐log	except	
for	the	DNMT3A	W860R	mutation	which	became	detectable	after	
therapy.	Stable	or	increasing	burden	of	mutations	detected	in	cfDNA	
at	CMR	implies	that	their	origins	are	CHIP	as	far	as	the	mutations	are	
known	to	be	commonly	present	in	CHIP.
As	for	dynamics	of	a	CHIP‐carrying	clone,	Wong	et	al.	reported	
that	33.3%	of	DNMT3A	mutations	and,	in	particular,	all	of	p.R882H,	
showed	 a	 significant	 increase,	 which	 was	 defined	 as	 more	 than	
twofold	with	a	P	value	<.05,	after	autologous	stem	cell	transplanta‐
tion.27	Only	the	TP53	p.C275Y	mutation	and	none	of	seven	DNMT3A 
mutations	 including	one	p.R882H	 fulfilled	 these	 criteria	 in	 the	 cur‐
rent	study.	Coombs	et	al.	also	reported	that	PPM1D and TP53 clonal 
hematopoiesis	 was	 detected	 in	 a	 mobilized	 stem‐cell	 product	 of	
patients	with	 lymphomas	at	a	higher	 frequency	compared	with	 the	
healthy	population.13	In	the	current	study,	TP53	CHIP‐carrying	clone	
in	one	patient	with	DLBCL	decreased	in	size	at	the	time	of	develop‐
ing	ANKL.	TP53	mutation	was	reportedly	observed	in	only	one	of	14	
ANKL	patients	 in	an	exome‐wide	sequencing	study.28	Although	de‐
tection	of	TP53‐CHIP	has	been	reported	as	a	risk	factor	for	develop‐
ing	 t‐MN,11‐13 some TP53‐carrying	CHIP	 clones	 themselves	 are	not	
founding	 leukemic	 clones.11	 The	 significance	of	monitoring	 a	 single	
specific	TP53‐CHIP‐carrying	clone	and	its	predictive	value	for	t‐MN	
remains	uncertain.
Herein,	we	raised	important	concerns	regarding	careful	evalua‐
tion	of	liquid	biopsy	in	B‐cell	lymphomas.	For	simplicity,	in	the	pres‐
ent	study,	screening	of	mutations	using	liquid	biopsy	was	carried	out	
at	 the	 time	of	CMR.	 If	 the	 screening	 is	 carried	 out	 at	 the	 time	of	
diagnosis,	relapse,	or	refractory	disease,	not	only	CHIP‐derived,	but	
also	tumor‐derived	TP53	mutations,	would	be	detected	(Figure	S4).	
In	 such	 settings,	 simultaneous	 sequencing	 of	 PBMC/BMMC,	 and	
lymphoma	samples,	 if	available,	may	be	 required	 to	determine	 the	
origins	of	mutations	detected	by	liquid	biopsy	and	to	interpret	their	
significance	appropriately.
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TA B L E  2  Longitudinal	analysis	of	TP53	p.A119D	mutation	in	the	patient	who	developed	ANKL
 Before therapy
After therapy 
(CMR) Relapse of DLBCL
After therapy 
(2nd CMR)
Diagnosis of 
ANKL
Concentration	of	TP53	p.A119D	
mutation	in	serum	(hGE/mL)
1.1	×	105 9.6	×	104 NA NA 2.1	×	106
VAF_serum	(%) 7.6 23.8 NA NA 3
VAF_DLBCL	(%) ND NA 1.8 NA NA
VAF_PBMC/BMMC	(%) 13.8a NA 23.8a 15.3 NAb
VAF_ANKL	(%) NA NA NA NA ND	(611/66	086	
reads)
Abbreviations:	ANKL,	aggressive	NK	cell	leukemia;	BMMC,	bone	marrow	mononuclear	cells;	CMR,	complete	metabolic	response;	DLBCL,	diffuse	
large	B‐cell	lymphoma;	NA,	not	available;	ND,	not	detectable;	VAF,	variant	allele	frequency.
aBone	marrow	invasion	was	not	observed	in	these	samples.	
bNearly	100%	of	peripheral	blood	cells	and	bone	marrow	cells	were	leukemic	cells	at	the	time	of	developing	ANKL.	
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